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Abstract 
Swelling and the progressive destruction of articular cartilage are major characteristics of rheumatoid arthritis (RA), a 
systemic autoimmune disease that directly affects the synovial joints and often causes severe disability in the affected 
positions. Recent studies have shown that type B synoviocytes, which are also called fibroblast-like synoviocytes 
(FLSs), as the most commonly and chiefly resident cells, play a crucial role in early-onset and disease progression by 
producing various mediators. During the pathogenesis of RA, the FLSs’ phenotype is altered, and represent invasive 
behavior similar to that observed in tumor conditions. Modified and stressful microenvironment by FLSs leads to the 
recruitment of other immune cells and, eventually, pannus formation. The origins of this cancerous phenotype stem 
fundamentally from the significant metabolic changes in glucose, lipids, and oxygen metabolism pathways. Moreover, 
the genetic abnormalities and epigenetic alterations have recently been implicated in cancer-like behaviors of RA 
FLSs. In this review, we will focus on the mechanisms underlying the transformation of FLSs to a cancer-like phe-
notype during RA. A comprehensive understanding of these mechanisms may lead to devising more effective and 
targeted treatment strategies.
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Background
Rheumatoid arthritis (RA) is a complex, systemic, and 
chronic autoimmune disorder that is recognized as the 
most common inflammatory arthropathy worldwide [1]. 
Although the disease can occur in all individuals and all 
age ranges, the prevalence is highest among women over 
40 years. The hallmark of the disease is a chronic inflam-
mation of the joints that is characterized by synovial 
membrane hypertrophy, hyperplasia, and symmetrical 
polyarthritis. The inflammation may destroy cartilage, 
bone, and formation of extra-articular manifestations 
(EAMs) [2], which ultimately leads to limitations, disabil-
ities, loss of function [2, 3], loss of quality of life [4], and 
increased morbidity and mortality [5]. Similar to most 
autoimmune diseases, RA is also a multifactorial disease. 
Based on studies on genetic predisposition in twins and 
families, the overall risk associated with genetic factors 
and heritability of RA is about 50–60% [6, 7]. Besides, 
cigarette smoking is the most important environmental 
factor involved in the disease onset, especially in people 
with a predisposing genetic background [8].
Specific fibroblasts located in the synovial mem-
brane of the joints are referred to as synovial fibro-
blasts (SFs) or fibroblast-like synoviocytes (FLSs) 
[9, 10], which is also referred as B-type synovio-
cytes versus A-type synoviocytes (macrophage-like 
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synoviocytes; MLSs). In recent years, FLSs have been 
introduced as the key players in the RA synovium [9, 
11]. FLSs are considered as the main source of carti-
lage degradation factors and inflammation [11]. In a 
normal physiological state, FLSs play an essential role 
in the homeostasis of the joints. Moreover, they play a 
chief role in releasing necessary synovial fluid compo-
nents. Conversely, in activated state and joint inflam-
matory conditions, FLSs lose their contact inhibition 
potential, alongside with high proliferation, reduced 
apoptosis, and increased expression of cytokines and 
chemokines, adhesions molecules, and matrix metal-
loproteinases (MMPs), which contribute to pannus 
formation as a critical player [10, 12]. Synovial hyper-
plasia is frequently seen in RA synovium, which results 
from the accumulation of FLSs and MLSs in a specific 
inflammatory microenvironment [12–14]. RA FLSs 
display cancerous properties in inflamed synovial tis-
sue, whereby they exhibit local tumor-like destructive 
and invasive characteristics [15, 16]. The phenotype, 
behavior, and role of FLSs in RA resemble the funda-
mental role of cancer-associated fibroblasts (CAFs) 
in various cancers [17, 18]. In this article, we aimed 
to review the FLS transformation in RA, tumor-like 
behaviors of RA FLSs, and discuss the underlying 
mechanisms in three principal axes of metabolism, 
genetics, and epigenetic modifications (Fig. 1).
FLSs and RA pathogenesis
FLSs are mesenchymal origin cells and particularly found 
in the synovium lining membrane, that exhibit many fea-
tures in common with fibroblasts, such as the expression 
of type IV and V collagens, and vimentin. On the other 
side, these cells also express specific surface markers, 
including Thy-1 membrane glycoprotein (CD90), decay-
accelerating factor (DAF; CD55) and secrete unique 
proteins, like lubricin and hyaluronic acid [synthesized 
by UDP-glucose 6-dehydrogenase (UDPGDH)] [9, 10]. 
Concerning cell adhesion, FLSs express vascular cell 
adhesion molecule-1 (VCAM-1) and cadherin-11 [19]. 
Cadherin-11, one of the major FLS markers, play a key 
role in activating and regulating the function of FLSs 
in addition to cell adhesion [20]. The concept that FLSs 
destroy the cartilage and supporting structures of the 
joint is supported by data in cadherin-11 knockout mice, 
in which the animal lacks an intimal lining, regardless of 
normal development. Despite an inflammatory state as 
well as the progression of bone destruction, these syn-
oviocyte-deficient mice do not present arthritis-induced 
cartilage damage [21].
The intimal lining of the RA synovium displays remark-
able changes, with a marked increase in cellular content, 
and the lining membrane of the RA synovium expands 
10–20-fold FLSs [22]. MLSs in RA synovium display a 
highly activated phenotype and produce pro-inflammatory 
Fig. 1 Three main axes of tumor-like behaviors of RA FLSs; metabolism, genetics and epigenetics modifications
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cytokines, chemokines, and growth factors. These prod-
ucts can activate local FLSs in the lining and induce them 
to produce their mediators, especially interleukin (IL)-6, 
prostanoids, and MMPs. This process establishes a parac-
rine/autocrine network that leads to synovitis, recruitment 
of further immune cells to the joint, and contribution to 
the destruction of the extracellular matrix. Among these, 
interactions between FLSs and synovial T lymphocytes 
have been reported strongly in vitro and in vivo [23, 24]. T 
lymphocytes, even in the resting state, have the ability to 
activate the FLSs and stimulate the production and secre-
tion of inflammatory mediators such as IL-6, IL-8, and 
prostaglandin E2 (PGE2) from them [25]. On the other 
hand, FLSs can also play an effective role in activating, pre-
senting super antigens and proliferative stimulation to T 
lymphocytes [26].
The hypertrophied synovial tissue, called ‘pannus’ at 
the cartilage-bone interface, masks the cartilage and 
erodes it towards the bone. The pannus, which is com-
posed of macrophages, osteoclasts, and invasive FLSs 
with relatively few lymphocytes, behaves like a locally 
invasive tumor [27]. With regards to FLSs’ aggressive 
properties, hyperplasia, and production of vast amounts 
of proteases, these cells act as primary players in bone 
and cartilage destruction in the inflamed joints [22].
The transformed phenotype of RA FLSs
During RA development, the phenotype of RA FLSs is 
altered to an invasive and aggressive form, with increased 
migration ability and reduced attachment-dependent 
growth, leading to intimal lining layer hyperplasia and 
the articular cartilage destruction and, ultimately, pan-
nus formation [9, 10]. Transformed FLSs in the inflam-
matory microenvironment of the RA synovium are not 
just “passive responders”, but as “imprinted aggressors” 
can continue to change their behaviors and phenotype, 
independently of external stimulation of the existing 
toxic and inflamed milieu [10, 28]. It appears that FLSs 
are inherently and permanently transformed, similar to 
the transformation of cancer cells. In this regard, it has 
been shown that this transformed phenotype of RA FLSs 
persists upon transplantation to severe combined immu-
nodeficiency (SCID) mouse model and this engraftment 
culminated in articular cartilage modulation through 
extracellular matrix destruction. Nonetheless, this behav-
ior has not been observed in FLSs isolated from healthy 
subjects or even cases with osteoarthritis (OA) [29]. Sig-
nificant differences in FLSs differentiation, proliferation, 
and adhesion are involved in divergences in the patterns 
and signature of DNA methylation in FLSs isolated from 
early RA individuals compared to that of patients with 
established RA [30]. Remarkably, studies that illustrate 
the role of FLSs in synovitis transition from an affected to 
a non-affected joint remind a process known as “metasta-
sis”, an important characteristic of cancerous cells patho-
genesis [29, 31, 32].
Cell metabolism in the transformed RA FLSs
One of the main metabolic hallmarks in RA patients is 
a significant increase in “calorie consumption” which 
resulted in increased heat in the involved joint. Following 
extensive studies to detect metabolic and mitochondrial 
changes in tumor cells of various malignancies, stud-
ies on the metabolic changes of immune cells, stromal 
cells, and fibroblasts in dysregulated and inflammatory 
conditions have been performed [33–37]. Daily intake 
of energy increases in RA as it has been reported an 8% 
higher basal metabolic rate (BMR) in non-smoker RA 
patients compared to healthy subjects (this increase was 
even 20% in smoker RA subjects) [38]. Increased dis-
ability, decreased quality of life, and early mortality of 
RA patients have also been attributed to the increased 
metabolism rate [39].
In the transformed FLSs, metabolism of the four main 
classes of macromolecules (carbohydrates, lipids, pro-
teins, and nucleic acids) changes, conferring an invasive 
potential to these cells [40, 41]. In general, glucose metab-
olism (i.e., glycolysis and pentose phosphate pathway), 
tricarboxylic acid (TCA) cycle, and amino acid metabo-
lisms, such as tyrosine-derived catecholamine and pro-
tein biosynthesis, in RA FLSs are severely impaired even 
compared to OA FLSs [42–44]. Investigation of the met-
abolic profile of RA synovial tissue has shown the main 
shift toward glucose and choline metabolism in RA FLSs 
[45–47].
Elevated glucose metabolism is one of the main char-
acteristics of the active and proliferating cells, similar 
to tumor cells. Increased metabolism of glucose and 
glycolysis process provides the required amounts of 
metabolic mediators to support the anabolic processes 
of lipids, nucleic acids, and proteins in proliferating 
RA FLSs [48]. Upregulated glucose metabolism in RA 
FLSs can contribute to inflammation and joint damage. 
In addition to overexpression of glucose transporter 1 
(GLUT1) and glucose uptake in RA FLSs, tumor necro-
sis factor-α (TNF-α) and platelet-derived growth factor 
(PDGF) induce the GLUT1 mRNA expression and glu-
cose metabolism. On the other hand, glucose depriva-
tion or inhibition of glycolysis by glycolytic inhibitors 
such as bromopyruvate (BrPa), disrupts the prolifera-
tion, migration, and cytokine secretion of RA FLSs. 
Additionally, in vivo experiments have established that 
inhibition of glycolysis strongly reduced the severity 
of arthritis [44]. Elevated chronic glucose metabolism 
due to hypoxia and highly pro-inflammatory mediators 
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in the microenvironment of the RA synovium, stimu-
lates and activates important signaling pathways in 
FLSs, including mitogen-activated protein kinase 
(MAPK), phosphatidylinositol-3-kinase (PI3K)/Akt, 
Janus kinase (JAK)/STAT, and hypoxia-inducible factor 
(HIF)-1α [49]. Eventually, upregulated glucose metabo-
lism in inflammatory conditions and arthritis-like RA 
resulted in increased serum lactate and succinate [50, 
51] (Fig. 2).
Raised levels of choline kinase (CK)-α (also known 
as choline phosphokinase), the primary enzyme of the 
choline pathway and phosphatidylcholine synthesis, 
has been shown to play a fundamental role in cell trans-
formation, invasion, and metastasis in various cancers 
[52–54]. CK is highly expressed in the RA synovial tis-
sue and cultured RA FLSs. So, CK inhibitors inhibit 
invasive properties, including cell migration and resist-
ance to apoptosis of FLSs in vivo, as well as a decel-
eration of arthritis development and amelioration of 
arthritis symptoms [47].
It has been documented that hypoxia can promote a 
switch to glycolysis, supporting abnormal angiogenesis, 
cellular invasion, and pannus formation [55]. In addi-
tion, glycolytic metabolites, including succinate [56], 
α-ketoglutarate, fumarate, and acetyl-CoA, are involved 
in changes in epigenetics and cell signaling [57]. Fur-
thermore, the accumulation of metabolic intermediates 
in FLSs under stress and hypoxic conditions contrib-
utes to anabolic mechanisms of nucleic acids, lipids, 
and proteins [41]. Interestingly, it has been reported 
that as RA progresses due to impairment in the lipids 
and glucose metabolism, the patients might be suscep-
tible to the co-occurrence of cardiovascular diseases 
(CVD) and metabolic syndrome [58].
Hyperplasia and resistance to apoptosis in RA FLSs
Increased proliferation of RA FLSs is one of the causes 
of RA synovial hyperplasia [59]. However, expression of 
proto-oncogenes, such as c-myc in FLSs, lack of mito-
sis as well as immunohistochemistry (IHC) staining for 
some markers of nuclear division, suggests that cell divi-
sion may not be the leading cause of synovial hyperplasia 
[41]. The limited number of mitotic divisions, the expres-
sion of Ki-67 as cell cycle marker, or the expression of 
proliferating cell nuclear antigen (PCNA), all suggest that 
DNA synthesis may predominantly not occur in RA FLSs 
[22].
 In addition to proliferation, apoptosis is another mech-
anism to control cell numbers in response to DNA dam-
age. It has been shown that significant changes occur in 
the mitochondrial pathways of apoptosis in RA FLSs, 
which leads to outstanding resistance to apoptosis. 
These changes include dysregulation of the Bcl-2 fam-
ily proteins, which plays a major role in the regulation of 
the intrinsic pathway of apoptosis [60, 61] as well as p53 
mutations, that explains the absence of apoptosis due to 
p53 impairments [62, 63]. It has been shown that inac-
tivation of the p53 protein by papillomavirus E6 protein 
in FLSs leads to increased growth rate and inhibited the 
apoptosis process [64].
Along with the established mechanisms involved in 
the regulation of apoptosis, it has been determined that 
Fig. 2 Increased and chronic glucose metabolism in RA-FLSs due to the presence in hypoxic microenvironment and abundant inflammatory 
mediators in the inflamed synovium
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the essential glycolytic enzymes can translocate to the 
nucleus, where they can play an anti-apoptotic role inde-
pendently of their canonical metabolic role. Hexokinase 
2 (HK2), which plays a typical role in the production of 
glucose 6-phosphate from glucose, can attach to the 
mitochondrial outer membrane through a transaction 
with the voltage-dependent anion channel (VDAC) pro-
tein [65]. The interaction between HK2 and VDAC pre-
vents the release of pro-apoptotic molecules and inhibits 
cell apoptosis. Interestingly, there is an overexpression of 
HK2 in RA FLSs compared to OA FLSs [44].
Dysregulation of angiogenesis in RA FLSs
Hypoxia is the primary mechanism for promoting the 
formation and development of new vessels [66, 67]. RA 
synovial hyperplasia, due to increased oxygen consump-
tion, causes an intensive hypoxic environment. Although 
the oxygen tension is up to 8% in healthy conditions, it is 
less than 1% in the toxic and highly hypoxic milieu of RA 
synovium [68]. Hypoxia results in HIF-α activation and 
overexpression, which induces the transcription of HIF-
responsive genes. Among these genes, vascular endothe-
lial growth factor (VEGF), fundamentally participates in 
synovial angiogenic processes, development of synovitis, 
and the RA pathogenesis [69].
Other angiogenic growth factors like fibroblast growth 
factor (FGF) and angiopoietin-2 are also secreted mainly 
by activated synovial FLSs and MLSs. Furthermore, 
hypoxia activates glycolytic enzymes like glucose 6-phos-
phate isomerase (G6PI) as well as glycolysis [70], which 
subsequently leads to the increased production and 
secretion of glycolytic intermediate components (like 
succinate and lactate). These components are potent 
angiogenic stimulants that play a useful role in sustain-
ing the process of angiogenesis [55, 71]. The angiogen-
esis, which means the formation of new vessels, has been 
implicated as one of the fundamental mechanisms in the 
pathogenesis of several autoimmune diseases including 
RA, OA and spondyloarthropathies. In RA, this process 
plays a key role in the over-migration and extravasation 
of the circulating immune cells to the inflammatory and 
hypertrophic joints and the supply of nutrients and oxy-
gen needed in their toxic environment [72, 73].
Migration, invasion, and metastasis of RA FLSs
In vitro experiments have indicated that RA FLSs play a 
prominent role in the cartilage tissue destruction, upon 
being co-cultured with the macrophage line U937. This 
finding demonstrated that the migration and invasion 
of FLSs had a fundamental role in the destruction of 
cartilage and the pannus formation in RA [74]. It has 
also been further reported that when FLSs isolated 
from RA patients are transplanted into SCID mice, dis-
play aggressive and destructive characteristics in the 
absence of other immune cells [29]. The initial bind-
ing of FLSs to the extracellular matrix components, 
namely proteoglycans and collagens, results in the acti-
vation of signaling pathways involved in their invasive 
behavior. Subsequently, it has been shown that inte-
grins, particularly the β1 family, are overexpressed in 
RA FLSs. Blocking these integrins on the surface of RA 
FLSs decreases the binding strength and their invasive 
capacity [75–77]. Communication and bilateral regu-
lation of integrin activation and cell metabolism is an 
emerging paradigm. Various metabolic pathways, such 
as AMP-activated protein kinase (AMPK), mammalian 
target of rapamycin complex 1 (mTORC1), and HIF-1α 
are involved in the regulation of integrins’ transcrip-
tion, function and expression on the cell surface [78, 
79]. On the other hand, integrins bilaterally regulate 
various metabolic pathways by linking to these path-
ways or directly interacting with metabolic enzymes 
[80].
Class 3 semaphorins genes, with their inhibitory role 
in the progression, migration, and invasion of vari-
ous cancers, were severely reduced in the synovium of 
RA patients. In particular, semaphorin-3B and sema-
phorin-3F reduce the migratory and invasive capacity 
of RA FLSs and suppress the expression of MMPs, thus 
being proposed as therapeutic targets in suppressing 
the invasive behavior of RA FLSs [81].
Platelet-derived growth factor (PDGF) levels in the 
RA synovium and synovial fluid has been plentifully 
reported [82–84]. In the pathogenesis of RA, PDGF is 
considered to be an important growth factor and stim-
ulate of production and secretion of the inflammatory 
mediators of FLSs, in synergistic association with trans-
forming growth factor-beta (TGF-β) [83, 85]. PDGF is 
essential for the formation of hypertrophic FLS archi-
tecture and the extracellular matrix-degrading inva-
dosome, invasion to cartilage, via activation of several 
signaling pathways, particularly the PI3K/AKT pathway 
[86]. Also, the intimal lining has been identified as the 
primary source of MMPs in RA, and is able to active 
FLSs with the secretion of collagenases and metallopro-
teinases, such as MMP-2 and MMP-9, and initiate the 
destruction of ECM and cartilage [87, 88].
In a recent comprehensive study on the role of differ-
ent immunological and non-immunological pathways 
in the behavior of RA FLSs, unexpectedly, the “Hun-
tington’s Disease Signaling” pathway and specifically 
huntingtin-interacting protein-1 (HIP1) was intro-
duced as the regulator of matrix invasion in RA FLSs 
[89]. Previous studies have also shown that HIP1 is 
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associated with cell movement and invasion in cancers 
[90, 91].
Genetic abnormalities involved in FLS cancer‐like 
behavior
The most critical genetic abnormalities occurred in the 
context of cancer-like behavior of RA FLSs are those 
that are also seen in tumors. For example, the p53 tumor 
suppressor gene has been observed to harbor mutations 
that contribute to cancerous consequences, including 
enhanced invasion and proliferation. Inazuka et al. found 
that there was a p53 mutation with plausible functional 
modification in four (44.4%) of the nine RA patients. 
Moreover, 10 cDNA subclones were identified to har-
boring ten p53 mutations, in which eight of them were 
associated with amino acid changes or truncated protein. 
Functional mutations of p53 were reported in the substi-
tution of Gly at amino acid residue 245 to Asp in two RA 
patients in three subclones. This mutation was suggested 
to may functionally affect the FLS, but the evidence was 
not strongly supportive of the role of p53 mutation in RA 
[92]. Nonetheless, P53R248Q mutation was reported to 
downregulate the expression of the pro-apoptotic mol-
ecule p53AIP1 in the MH7A RA FLS cell line, resulting in 
a decreased apoptosis rate and, increasing the tumor-like 
proliferation of these cells [93]. It seems that p53 muta-
tions are induced by genotoxic exposure randomly, which 
may be seen in a small number of RA synoviocytes that 
were present in both erosive and non-erosive areas of 
the synovium. Moreover, the most important contribut-
ing factor for invasive behavior of the cells might be the 
vicinity of bone and cartilage instead of harboring a p53 
mutation [94]. On the other hand, it should be noted 
that p53 positive cells might not be present in all of the 
synovial tissues of RA subjects [95]. Nonetheless, several 
other studies have reported upregulated expression of 
p53 in RA FLSs [96–98]. In line with these observations, 
abnormalities were identified in the p53 in RA patients; 
nonetheless, they were not associated with the cancerous 
characteristics of the rheumatoid synovium, as evaluated 
by proliferative manifestations [99].
Except than p53 tumor suppressor gene, other genetic 
abnormalities have also been reported to be involved in 
the cancerous behavior of FLSs. Dual-specificity tyros-
ine-regulated kinase 1A (Dyrk1A), a regulator of the 
MAPK pathway activation, plays a role in the prolifera-
tion and differentiation of mammalian cells. An overex-
pression of Dyrk1A was observed in the RA synovial 
tissues as well as in a TNF-α-induced FLSs activation 
model. It was demonstrated that Dyrk1A might increase 
the cancerous traits of FLSs, including proliferation, 
migration, and invasion through suppressing the expres-
sion of sprouty RTK signaling antagonist 2 (Spry2) and 
activating the MAPK/ERK signaling pathway in RA [100]. 
B-Raf proto-oncogene, serine/threonine kinase (BRAF) is 
also involved in the regulation of the MAPK/ERK sign-
aling pathway and finally impresses the cell division and 
differentiation. The V600R gain-of-function mutation of 
BRAF, which has been associated with several cancers, 
was also identified in the RA synovial fibroblasts. How-
ever, only two of the nine evaluated subjects indicated 
this mutation. V600R mutation plays a role in the fibro-
blast transformation, which in turn was involved in the 
destruction of articular cartilage and bone in RA [101].
Aberrant activation of the sonic hedgehog (SHH) 
signaling pathway plays a vital role in tumor formation 
and development. Besides, the SHH signaling pathway 
through the MAPK/ERK pathway was found to regulate 
proliferation, migration and tumor-like behavior of RA 
FLSs [102]. In this regard, it was suggested that targeting 
the SHH pathway can be considered as an effective thera-
peutic strategy in RA patients.
Genetic variations in the cytokine genes have also been 
evaluated with respect to the cancerous behaviors of the 
RA FLSs. The IL-10 genotype, which is associated with 
RA progression, did not influence the invasiveness of the 
RA FLSs when the − 2849 non-G carriers were compared 
to those who were G carriers. However, the adenoviral 
gene transfer of IL-10 to FLSs resulted in the inhibition of 
FLS invasiveness [103].
Epigenetic abnormalities involved in cancer‐like 
behavior of FLS
Epigenetics is characterized as stable and heritable altera-
tions in gene expression without changes in the DNA 
sequence [104]. Epigenetic modifications (DNA meth-
ylation, histone modifications, and non-coding RNAs), 
modulate gene expression patterns during normal physi-
ological processes and also in response to environmental 
factors (Table  1). The cellular phenotype and function 
could be modulated through various epigenetic patterns, 
named the epigenetic signature. There are many epige-
netic modifications in the RA FLSs, which are capable of 
being involved in RA pathogenesis [105].
DNA methylation abnormalities
It has been documented that the methylation pattern of 
the FLS cells is different in RA and OA patients [106]. It is 
important to notice that DNA methylation and transcrip-
tion patterns are different in the RA FLS cells isolated 
from various joints. These findings indicate that there is 
a complex and joint-specific relationship between gene 
expression and DNA methylation in modulating joint 
inflammation at different anatomical locations [107]. 
Subsequently, investigation on the peripheral blood (PB) 
lymphocytes in RA patients showed that the genome is 
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hyper-methylated. Therefore, the DNA methylation sig-
nature of PB-lymphocytes could be considered as a risk 
indicator [108]. Genes with different methylation pattern 
in PB-lymphocytes are involved in focal adhesion, cell 
migration, and extracellular matrix interactions, which 
resulted in chronic inflammation in RA [109]. Analysis of 
methylation patterns showed that the differences are seen 
in integrin, PDGF, and Wnt pathway genes and propose 
that cell imprinting linked to adhesion, differentiation, 
and proliferation changes through the disease develop-
ment [110].
Limb bud and heart development (LBH) deficiency lead 
to an increase in DNA damage and cell cycle arrest in the 
S-phase. Furthermore, in  vivo, LBH deficiency causes 
abnormalities in the cell cycle and increases the severity 
of arthritis in a mouse model [111]. A combination of the 
differentially methylated loci (DML) with a risk variant 
regulates the LBH expression and function, elucidating 
how epigenetic mechanisms and genetic risk can interact 
to change cellular function [112]. Tyrosine-Protein phos-
phatase non-receptor type 11 (PTPN11), encodes the 
protein tyrosine phosphatase SHP2, showed an elevated 
expression level in the RA FLSs and played a critical role 
in the migration of the cells. It has been shown that low 
expression of SHP2 in the serum transfer mouse model is 
associated with low disease activity, demonstrating that it 
could be a potential therapeutic target. Methylation of an 
intronic enhancer of PTPN11 could increase the expres-
sion of SHP2 in the RA FLSs [113].
It has been shown that there is an increased expression 
(30–300 fold) in long interspersed element 1 (LINE1) 
in the RA FLSs, compared with the normal FLSs, and 
its expression is regulated by the DNA methylation 
mechanism [114]. Investigations on the RA FLS cells pro-
pose that LINE1 is associated with the aggressive pheno-
type of these cells through regulation of stress-activated 
protein kinase (SAPK) [p38 MAPK] signaling cascades, 
which is a part of a kinase pathway that leads to the 
production of cytokines including IL-8, IL-6 [115], and 
MMPs [116].
Histone modifications
In histone deacetylase (HDACs) evaluation, two HDACs; 
HDAC1 and − 2, were upregulated in the RA FLSs 
compared with the OA FLSs. It has been reported that 
knockdown of these two HDACs might lead to low pro-
liferation and high apoptosis of the RA FLS cells [117]. 
Since the RA FLSs have aggressive behavior, like cancer 
cells, and many investigations have shown benefits from 
HDAC inhibitors in cancer therapy, these kinds of treat-
ment could be an option in the case of RA. Trichosta-
tin A is one of the important HDAC inhibitors that has 
been widely used to inhibit the aggressiveness of the RA 
FLSs [118]. Studies have illustrated that treatment of the 
RA FLSs with trichostatin A could decrease invasive-
ness [113] and inflammatory responses [119] as well as 
increase apoptosis [113, 120–122]. The low proliferation 
of the FLSs could be mediated by inhibition of cell-cycle 
progression, and the high apoptosis could be applied 
through high expression of pro-apoptotic genes [123]. 
In vitro studies have shown that combination therapy of 
SAHA and MS-275, histone deacetylase inhibitors, could 
prevent the proliferation of the FLSs [124]. Furthermore, 
HDACs have lots of non-histone targets such as P53, a 
critical gene in regulating cell proliferation and apop-
tosis, which is downregulated through HDACs [125]. 
Table 1 Epigenetic abnormalities of the RA FLS concerning cancer-like behavior
Name Status Function References
PTPN11 Hypomethylated Migration [113]
LINE1 Hypomethylated Aggressiveness [114]
HDAC1 and 2 Upregulated Apoptosis and proliferation [117]
miR-10a Downregulated Migration, proliferation, invasion [128, 129]
miR-27a Downregulated Invasion and migration [130, 131]
miR-30a Downregulated Autophagy [132]
miR-34a Downregulated Apoptosis [133, 147]
miR-15a Downregulated Apoptosis [134]
miR-124a Downregulated Proliferation [132]
miR-155 Downregulated The proliferation and invasive behavior [136, 139]
miR-126 Upregulated Apoptosis [135]
miR-221 Upregulated Invasion and migration [140]
miR-663 Upregulated Proliferation [141]
miR-21 Upregulated Proliferation [142]
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Investigations on animal models of RA have shown that 
general HDAC inhibitors could decrease disease severity 
[124, 126, 127]. Furthermore, they have documented that 
HDACs play a critical role in RA pathogenesis by modi-
fying the FLSs.
MicroRNA abnormalities
In respect to microRNAs in the RA FLSs, a recent study 
has shown that there is a different signature of microRNA 
expression in the RA FLSs compared to the OA FLSs. Of 
these, the expression of miR-10a in the RA synovial tissue 
and the FLSs was significantly lower than the OA FLSs. 
Pro-inflammatory cytokines such as IL-1b and TNF 
result in decreased expression of miR-10a through the 
nuclear factor (NF)-κB pathway. This microRNA targets 
various genes in the TNF/IL1 signaling pathway include 
BTRC (beta-transducin repeat containing E3 ubiquitin-
protein ligase), nuclear receptor subfamily 2 group C 
member 2 (NR2C2), and interleukin-1 receptor-associ-
ated kinase 4 (IRAK4) [128]. Upregulation of miR-10a 
decreases the expression of C-C motif chemokine ligand 
2 (CCL2), matrix metallopeptidase (MMP)-1, MMP-13, 
IL-6, and IL-8 and reduces migration, proliferation, and 
invasion of the RA FLSs [129]. Another microRNA with 
a reduced expression profile is miR-27a, which its expres-
sion is highly downregulated in FLSs, synovial tissue, and 
serum of RA patients compared to healthy controls. This 
study further illustrated that mimic of miR-27a could 
markedly inhibit invasion and migration of the RA FLSs 
through downregulating of MMP-2/9/13 and invasion-
related proteins such as RhoA, Rac1, and Cdc42. Fur-
thermore, miR-27a reduce NF-kB p65 and TLR4 protein 
levels. Another molecule that is regulated by miR-27a is 
follistatin-like protein 1 (FSTL1), a pro-inflammatory 
mediator with high expression pattern in RA serum 
and synovium, especially in patients with positive anti-
citrullinated protein antibodies (ACPA) [130]. Further-
more, upregulation of miR-27a could increase invasion 
and migration of the RA FLSs through downregulating 
the FSTL1, which consequently led to inhibiting of the 
NF-κB signaling pathway in the RA FLS [131].
A study has shown that the miR-30a expression is 
reduced in RA patients, compared with healthy controls. 
Due to miR-30a interactions with Beclin-1, autophagy 
marker, it was linked to autophagy [132]. Since the 
miR-34a has been suggested as a regulatory factor for 
apoptosis, therefore it is linked to the RA FLSs lifes-
pan. Evaluation on miR-34a expression and apoptosis by 
Niederer et  al. has illustrated that the miR-34a targets 
X-linked inhibitor of apoptosis protein (XIAP). They have 
documented that there is a negative correlation between 
high expression of XIAP and low expression of miR-34a 
in RA FLSs and eventually low expression of miR-34a 
could lead to apoptosis resistance [133]. In the case of 
apoptosis, downregulation of miR-15a in the RA FLSs has 
been reported. Since miR-15a directly targets B cell lym-
phoma 2 (Bcl-2), which is associated with cell survival, its 
regulatory role in suppressing Bcl-2 ultimately leads to 
increased FLS apoptosis in the collagen-induced arthritis 
(CIA) mice model [134]. Gao et al. have documented that 
targeting phosphoinositide-3-kinase regulatory subunit 2 
(PIK3R2) by miR-126 may modulate apoptosis of the RA 
FLSs through interfering with the PI3k/AKT signaling 
pathway [135].
It has been documented that the cyclin-dependent 
kinase 2 (CDK2) expression could be regulated by the 
miR-124a, which is associated with MCP-1 secretion and 
synoviocyte proliferation [132]. Later studies have evalu-
ated the methylation profile of the promoter region of 
miR-124a in the OA and RA synoviocyte tissue and illus-
trated that the promoter region in the RA patients was 
significantly hypermethylated, compared with the OA 
patients. Hypermethylation of miR-124a might be cor-
related with its low expression [136], which is correlated 
to a high proliferation of synoviocytes [137]. Besides, 
miR-146a can act as a key epigenetic regulator of inflam-
mation in RA, and in regulating the metabolic activity 
of synovial fibroblasts and their bone destruction [138]. 
Downregulation of miR-155 in the RA FLSs leads to pro-
liferation and high production of MMP-3. Therefore, 
overexpression of miR-155 results in decreased MMP-3 
production, proliferation and invasive behavior; so, miR-
155 could be a therapeutic target [136]. Nonetheless, 
miR-155 has various functions and implicated in many 
immune regulatory mechanisms such as; T cell-depend-
ent inflammatory responses, T cell-dependent antibody 
responses, Treg suppressive functions, B cell develop-
ment, and activation of tissue macrophages; therefore, it 
is hard to propose it as a therapeutic marker. One of the 
validated targets for miR-155 is inositol polyphosphate-
5-phosphatase D (INPP5D), which has an inhibitory 
effect on the proliferation of lymphoid and myeloid cells; 
therefore, the deregulation of miR-155 might lead to 
fibroblast proliferation and resident myeloid cell infiltra-
tion [139]. The analysis showed that the miR-221 silenc-
ing could decrease the invasion and migration of the RA 
FLSs [140].
High expression of miR-663 increases various key dis-
ease targets during the RA development and finally leads 
to the high proliferation of the RA FLSs [141]. Investiga-
tions have illustrated that the miR-21 silencing in the RA 
FLSs is associated with low expression of NF-κB and also 
the low proliferation rate of the RA FLSs. On the other 
hand, high expression of miR-21 was linked with the high 
level of NF-κB and the elevated level of proliferation in 
the RA FLSs. Further investigations have illustrated that 
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miR-21 through facilitating NF-κB translocation and 
affecting the NF-κB pathway could increase the prolifera-
tion of the RA FLSs [142].
LncRNA abnormalities
Long non-coding RNAs (lncRNAs) are RNA molecules 
containing further than 200 nucleotides in length [143]. 
lncRNAs play a role in the regulating of genes transcrip-
tion in several ways, such as RNA sponging, alternative 
splicing, and epigenetic mechanisms [144]. Aberrant 
expression of lncRNAs has been reported in FLSs from 
RA patients and that of healthy individuals that were 
also involved in clinicopathological manifestations of RA 
patients [128]. Nonetheless, little has been revealed about 
the involvement of lncRNAs in the cancerous behav-
iors of RA FLSs. Ye et  al. have reported that the silenc-
ing of lncRNA ZFAS1 (which is upregulated in RA FLSs) 
leads to the reduced migration and invasion in RA FLSs. 
They have reported that lncRNA ZFAS1 is involved in 
the migration and invasion of RA FLSs through regulat-
ing of miR-27a transcription [145]. Another lncRNA, 
metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1), has been reported to play a role in the apop-
tosis of RA FLSs via repressing the PI3K/AKT signaling 
[146]. Hence, lncRNAs are involved in the modulation 
of genes with the implication in the cancerous behaviors 
of RA FLSs. Altogether, this is a nascent field of research 
that needs to be enrichened with comprehensive data to 
let us come up with the understanding of the decisive 
implication of lncRNAs in the cancerous behaviors of RA 
FLSs, for designing future diagnostic tools as well as ther-
apeutic approaches.
Concluding remarks
Interactions between the structural components of the 
synovial environment, such as synoviocytes with differ-
ent cells of immune system, such as T lymphocytes, may 
play a pivotal role in the ethiopathogenesis of RA dis-
ease. Meanwhile, in recent years, FLSs have been intro-
duced as the chief cells involved in the initial onset, the 
development and spread of synovitis, and, ultimately, the 
destruction of the adjacent joint and bones. Active and 
transformed RA FLS at the synovial site, with high pro-
liferation, resistance to apoptosis, invasion, metastatic 
behavior, and induction of angiogenesis, play a cancerous 
role in RA pathogenesis. The phenotype and cancer-like 
behavior of FLSs in RA remind the behavior of CAFs in 
various neoplasms. This study reviewed the different var-
iations of FLSs that led to their cancer-like behavior (in 
the metabolism, genetics, and epigenetics areas).
Today, the fundamental role of FLSs in the develop-
ment of synovial hyperplasia, chronic inflammation, 
invasion, and articular cartilage destruction has been 
identified. The metabolic, genetic, and epigenetic altera-
tions involved in the transformation of these cells are also 
somewhat determined. To better understand the behav-
ior of RA FLS in the inflammatory milieu, further stud-
ies are required, focusing on similarities to cells that form 
the cancerous microenvironment, in particular, CAFs. It 
is hoped to take a fundamental step toward achieving a 
targeted and effective therapeutic strategy, with a clear 
understanding of the behavior of RA FLS and its main 
contributing factors.
Abbreviations
ACPA: Anti-citrullinated protein antibodies; AMPK: AMP-activated protein 
kinase; Bcl-2: B cell lymphoma 2; BMR: Basal metabolic rate; BRAF: B-Raf proto-
oncogene, serine/threonine kinase; BrPa: Bromopyruvate; BTRC : Beta-trans-
ducin repeat containing E3 ubiquitin-protein ligase; CAFs: Cancer-associated 
fibroblasts; CCL2: Chemokine ligand 2; CDK2: Cyclin-dependent kinase 2; CK: 
Choline kinase; CVD: Cardiovascular diseases; DAF: Decay-accelerating factor; 
DML: Differentially methylated loci; Dyrk1A: Dual-specificity tyrosine-regulated 
kinase 1A; EAMs: Extra-articular manifestations; FGF: Fibroblast growth factor; 
FLS: Fibroblast-like synoviocyte; FSTL1: Follistatin-like protein 1; G6PI: Glucose 
6-phosphate isomerase; GLUT1: Glucose transporter 1; HDACs: Histone 
deacetylase; HK2: Hexokinase 2; IHC: Immunohistochemistry; IL: Interleu-
kin; INPP5D: Inositol polyphosphate-5-phosphatase D; IRAK4: Interleukin-1 
receptor-associated kinase 4; JAK: Janus kinase; LBH: Limb bud and heart 
development; LINE1: Long interspersed element 1; lncRNAs: Long non-coding 
RNAs; MALAT1: Metastasis-associated lung adenocarcinoma transcript 1; 
MAPK: Mitogen-activated protein kinase; MLS: Macrophage-like synoviocytes; 
MMP: Matrix metalloproteinases; MMP: Matrix metallopeptidase; mTORC1: 
Mammalian target of rapamycin complex 1; NF: Nuclear factor; NR2C2: Nuclear 
receptor subfamily 2 group C member 2; OA: Osteoarthritis; PB: Peripheral 
blood; PCNA: Proliferating cell nuclear antigen; PDGF: Platelet-derived growth 
factor; PDGF: Platelet-derived growth factor; PI3K: Phosphatidylinositol-
3-kinase; PIK3R2: Phosphoinositide-3-kinase regulatory subunit 2; PTPN11: 
Tyrosine-Protein phosphatase non-receptor type 11; RA: Rheumatoid arthritis; 
SAPK: Stress-activated protein kinase; SCID: Severe combined immunode-
ficiency; SF: Synovial fibroblasts; Spry2: Sprouty RTK signaling antagonist 2; 
TCA : Tricarboxylic acid; TGF-β: Transforming growth factor-beta; TNF-α: Tumor 
necrosis factor-α; UDPGDH: UDP-glucose 6-dehydrogenase; VCAM-1: Vascular 
cell adhesion molecule-1; VDAC: Voltage-dependent anion channel; VEGF: Vas-




MJA, JK, and SA contributed to acquisition and interpretation of data‎ and 
drafting the article. MNT contributed to the conception and design of the 
study and drafting the article. ASV contributed to acquisition and interpreta-
tion of data and revising the article critically for important intellectual content. 
AJ, EF*, and MM* contributed to the conception and design of the study and 
revising the article critically for important intellectual content. All authors 
contributed to manuscript revision, read, and approved the submitted version.
Funding
This research did not receive any specific grant from funding agencies in the 
public, commercial, or not-for-profit sectors.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Competing interests
The authors declare that there are no conflicts of interest.
Page 10 of 13Mousavi et al. Autoimmun Highlights            (2021) 12:3 
Author details
1 Rheumatology Research Center, Tehran University of Medical Sciences, 
Tehran, Iran. 2 Department of Immunology, School of Medicine, Tehran Uni-
versity of Medical Sciences, Tehran, Iran. 3 Department of Hematology, Faculty 
of Allied Medicine, Bushehr University of Medical Sciences, Bushehr, Iran. 
4 Department of Immunology, School of Medicine, Iran University of Medical 
Sciences, Tehran, Iran. 5 Department of Laboratory Sciences, Khomein Univer-
sity of Medical Sciences, Khomein, Iran. 6 Joint Reconstruction Reseach Center, 
Tehran University of Medical Sciences, Tehran, Iran. 7 Inflammation Research 
Center, Tehran University of Medical Sciences, Tehran, Iran. 
Received: 29 July 2020   Accepted: 20 October 2020
References
 1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 
2010;376(9746):1094–108.
 2. Amaya-Amaya J, Botello-Corzo D, Calixto OJ, Calderon-Rojas 
R, Dominguez AM, Cruz-Tapias P, et al. Usefulness of patients-
reported outcomes in rheumatoid arthritis focus group. Arthritis. 
2012;2012:935187.
 3. Sokka T, Krishnan E, Hakkinen A, Hannonen P. Functional disability in 
rheumatoid arthritis patients compared with a community population 
in Finland. Arthritis Rheum. 2003;48(1):59–63.
 4. Cadena J, Vinaccia S, Perez A, Rico MI, Hinojosa R, Anaya JM. The impact 
of disease activity on the quality of life, mental health status, and family 
dysfunction in colombian patients with rheumatoid arthritis. J Clin 
Rheumatol. 2003;9(3):142–50.
 5. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 
update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):35–61.
 6. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. 
Characterizing the quantitative genetic contribution to rheumatoid 
arthritis using data from twins. Arthritis Rheum. 2000;43(1):30–7.
 7. Karami J, Aslani S, Jamshidi A, Garshasbi M, Mahmoudi M. Genetic 
implications in the pathogenesis of rheumatoid arthritis; an updated 
review. Gene. 2019;9:78.
 8. Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC. Smoking increases 
rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 
shared epitope, regardless of rheumatoid factor or anti-cyclic citrul-
linated peptide antibody status. Arthritis Rheum. 2010;62(2):369–77.
 9. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in 
rheumatoid arthritis. Immunol Rev. 2010;233(1):233–55.
 10. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: 
passive responders and imprinted aggressors. Nat Rev Rheumatol. 
2013;9(1):24–33.
 11. Ganesan R, Rasool M. Fibroblast-like synoviocytes-dependent effector 
molecules as a critical mediator for rheumatoid arthritis: current status 
and future directions. Int Rev Immunol. 2017;36(1):20–30.
 12. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J 
Med. 2011;365(23):2205–19.
 13. Izquierdo E, Canete JD, Celis R, Del Rey MJ, Usategui A, Marsal S, et al. 
Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopatho-
logic correlations and partial reversal by anti-tumor necrosis factor 
therapy. Arthritis Rheum. 2011;63(9):2575–83.
 14. Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, et al. 
Analysis of the histologic variation of synovitis in rheumatoid arthritis. 
Arthritis Rheum. 1988;31(8):956–63.
 15. Guo J, Zhao W, Cao X, Yang H, Ding J, Ding J, et al. SIRT1 promotes 
tumor-like invasion of fibroblast-like synoviocytes in rheumatoid arthri-
tis via targeting TIMP1. Oncotarget. 2017;8(51):88965–73.
 16. Liu Y, Pan YF, Xue YQ, Fang LK, Guo XH, Guo X, et al. uPAR promotes 
tumor-like biologic behaviors of fibroblast-like synoviocytes through 
PI3K/Akt signaling pathway in patients with rheumatoid arthritis. Cell 
Mol Immunol. 2018;15(2):171–81.
 17. Bhattaram P, Jones K. Regulation of fibroblast-like synoviocyte 
transformation by transcription factors in arthritic diseases. Biochem 
Pharmacol. 2019;2:345.
 18. Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts build 
and secure the tumor microenvironment. Front Cell Develop Biol. 
2019;7:7.
 19. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of syno-
vial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 
2000;2(5):361–7.
 20. Kiener HP, Niederreiter B, Lee DM, Jimenez-Boj E, Smolen JS, Brenner 
MB. Cadherin 11 promotes invasive behavior of fibroblast-like synovio-
cytes. Arthritis Rheum. 2009;60(5):1305–10.
 21. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al. Cad-
herin-11 in synovial lining formation and pathology in arthritis. Science. 
2007;315(5814):1006–10.
 22. Firestein GS, Kelley WN. Kelley’s textbook of rheumatology. Philadelphia: 
Elsevier/Saunders; 2013.
 23. Tran CN, Thacker SG, Louie DM, Oliver J, White PT, Endres JL, et al. Inter-
actions of T cells with fibroblast-like synoviocytes: role of the B7 family 
costimulatory ligand B7-H3. J Immunol. 2008;180(5):2989–98.
 24. Tran CN, Lundy SK, White PT, Endres JL, Motyl CD, Gupta R, et al. 
Molecular interactions between T cells and fibroblast-like synoviocytes: 
role of membrane tumor necrosis factor-alpha on cytokine-activated T 
cells. Am J Pathol. 2007;171(5):1588–98.
 25. Yamamura Y, Gupta R, Morita Y, He X, Pai R, Endres J, et al. Effector 
function of resting T cells: activation of synovial fibroblasts. J Immunol. 
2001;166(4):2270–5.
 26. Tsai C, Diaz LA Jr, Singer NG, Li LL, Kirsch AH, Mitra R, et al. Responsive-
ness of human T lymphocytes to bacterial superantigens presented 
by cultured rheumatoid arthritis synoviocytes. Arthritis Rheum. 
1996;39(1):125–36.
 27. Shiozawa S, Shiozawa K, Fujita T. Morphologic observations in the early 
phase of the cartilage-pannus junction. Light and electron microscopic 
studies of active cellular pannus. Arthritis Rheum. 1983;26(4):472–8.
 28. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. 
Passive responders or transformed aggressors? Arthritis Rheum. 
1996;39(11):1781–90.
 29. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay 
RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach 
to and invade normal human cartilage when engrafted into SCID mice. 
Am J Pathol. 1996;149(5):1607–15.
 30. Ai R, Whitaker JW, Boyle DL, Tak PP, Gerlag DM, Wang W, et al. DNA 
Methylome Signature in Synoviocytes From Patients With Early Rheu-
matoid Arthritis Compared to Synoviocytes From Patients With Long-
standing Rheumatoid Arthritis. Arthritis Rheumatol. 2015;67(7):1978–80.
 31. Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. 
Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. 
Nat Med. 2009;15(12):1414–20.
 32. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, 
et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
 33. Ramsay EE, Hogg PJ, Dilda PJ. Mitochondrial metabolism inhibitors for 
cancer therapy. Pharm Res. 2011;28(11):2731–44.
 34. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lym-
phocytes. Annu Rev Immunol. 2013;31:259–83.
 35. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism 
of stromal and immune cells in health and disease. Nature. 
2014;511(7508):167–76.
 36. Yin Y, Choi SC, Xu Z, Perry DJ, Seay H, Croker BP, et al. Normaliza-
tion of CD4 + T cell metabolism reverses lupus. Sci Transl Med. 
2015;7(274):274ra18.
 37. McDonald G, Deepak S, Miguel L, Hall CJ, Isenberg DA, Magee AI, et al. 
Normalizing glycosphingolipids restores function in CD4 + T cells from 
lupus patients. J Clin Invest. 2014;124(2):712–24.
 38. Metsios GS, Stavropoulos-Kalinoglou A, Nevill AM, Douglas KM, 
Koutedakis Y, Kitas GDJ. Cigarette smoking significantly increases 
basal metabolic rate in patients with rheumatoid arthritis. Gene. 
2008;67(1):70–3.
 39. Rall L, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, 
mechanisms and interventions. Rheumatology. 2004;43(10):1219–23.
 40. Guma M, Tiziani S, Firestein GS. Metabolomics in rheumatic diseases: 
desperately seeking biomarkers. Nat Rev Rheumatol. 2016;12(5):269–81.
 41. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-
like synoviocyte metabolism in the pathogenesis of rheumatoid 
arthritis. Arthritis Res Ther. 2017;19(1):110.
Page 11 of 13Mousavi et al. Autoimmun Highlights            (2021) 12:3  
 42. Ahn JK, Kim S, Hwang J, Kim J, Kim KH, Cha HS. GC/TOF-MS-based 
metabolomic profiling in cultured fibroblast-like synoviocytes from 
rheumatoid arthritis. Joint Bone Spine. 2016;83(6):707–13.
 43. Kim S, Hwang J, Xuan J, Jung YH, Cha H-S, Kim KH. Global metabolite 
profiling of synovial fluid for the specific diagnosis of rheumatoid 
arthritis from other inflammatory arthritis. PLoS One. 2014;9(6):e97501.
 44. Garcia-Carbonell R, Divakaruni AS, Lodi A, Vicente-Suarez I, Saha 
A, Cheroutre H, et al. Critical Role of Glucose Metabolism in Rheu-
matoid Arthritis Fibroblast-like Synoviocytes. Arthritis Rheumatol. 
2016;68(7):1614–26.
 45. Volchenkov R, Dung Cao M, Elgstoen KB, Goll GL, Eikvar K, Bjorneboe O, 
et al. Metabolic profiling of synovial tissue shows altered glucose and 
choline metabolism in rheumatoid arthritis samples. Scand J Rheuma-
tol. 2017;46(2):160–1.
 46. Ahn JK, Kim S, Hwang J, Kim J, Kim KH, Cha H-S. GC/TOF-MS-based 
metabolomic profiling in cultured fibroblast-like synoviocytes from 
rheumatoid arthritis. Joint Bone Spine. 2016;83(6):707–13.
 47. Guma M, Sanchez-Lopez E, Lodi A, Garcia-Carbonell R, Tiziani S, Karin M, 
et al. Choline kinase inhibition in rheumatoid arthritis. Ann Rheum Dis. 
2015;74(7):1399–407.
 48. Matsui T, Nakata N, Nagai S, Nakatani A, Takahashi M, Momose T, et al. 
Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by 
cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 
2009;50(6):920–6.
 49. de Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. 
Fibroblast-like synoviocytes glucose metabolism as a therapeutic target 
in rheumatoid arthritis. Front Immunol. 2019;10:1743.
 50. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The 
impact of inflammation on metabolomic profiles in patients with arthri-
tis. Arthr Rhuem. 2013;65(8):2015–23.
 51. Jiang M, Chen T, Feng H, Zhang Y, Li L, Zhao A, et al. Serum meta-
bolic signatures of four types of human arthritis. J Proteome Res. 
2013;12(8):3769–79.
 52. de Molina AR, Gallego-Ortega D, Sarmentero-Estrada J, Lagares D, del 
Pulgar TG, Bandrés E, et al. Choline kinase as a link connecting phos-
pholipid metabolism and cell cycle regulation: Implications in cancer 
therapy. Int J Biochem Cell Biol. 2008;40(9):1753–63.
 53. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant 
transformation. Nat Rev Cancer. 2011;11(12):835.
 54. de Molina AR, Bánez-Coronel M, Gutiérrez R, Rodríguez-González A, 
Olmeda D, Megías D, et al. Choline kinase activation is a critical require-
ment for the proliferation of primary human mammary epithelial cells 
and breast tumor progression. Cancer Res. 2004;64(18):6732–9.
 55. Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, et al. 
Dysregulated bioenergetics: a key regulator of joint inflammation. Ann 
Rheum Dis. 2016;75(12):2192–200.
 56. Mills E, O’Neill LA. Succinate: a metabolic signal in inflammation. Trends 
Cell Biol. 2014;24(5):313–20.
 57. Zhu H, Chen L, Zhou W, Huang Z, Hu J, Dai S, et al. Over-expression of 
the ATP5J gene correlates with cell migration and 5-fluorouracil sensi-
tivity in colorectal cancer. PloS one. 2013;8(10):e76846.
 58. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CDJM. Metabolic syndrome in 
rheumatoid arthritis. Mediators Inflamm. 2012;7(2):148.
 59. Matsuo Y, Mizoguchi F, Saito T, Kawahata K, Ueha S, Matsushima K, et al. 
Local fibroblast proliferation but not influx is responsible for synovial 
hyperplasia in a murine model of rheumatoid arthritis. Biochem Bio-
phys Res Commun. 2016;470(3):504–9.
 60. Matsumoto S, Muller-Ladner U, Gay RE, Nishioka K, Gay S. Ultrastructural 
demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid 
synovial fibroblasts. J Rhuematol. 1996;23(8):1345–52.
 61. Lee SY, Kwok SK, Son HJ, Ryu JG, Kim EK, Oh HJ, et al. IL-17-mediated 
Bcl-2 expression regulates survival of fibroblast-like synoviocytes 
in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther. 
2013;15(1):R31.
 62. Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and 
proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum. 
2006;54(2):587–92.
 63. You X, Boyle DL, Hammaker D, Firestein GS. PUMA-mediated apoptosis 
in fibroblast-like synoviocytes does not require p53. Arthritis Res Ther. 
2006;8(6):R157.
 64. Aupperle KR, Boyle DL, Hendrix M, Seftor EA, Zvaifler NJ, Barbosa M, 
et al. Regulation of synoviocyte proliferation, apoptosis, and invasion by 
the p53 tumor suppressor gene. Am J Pathol. 1998;152(4):1091–8.
 65. Yu X, Li S. Non-metabolic functions of glycolytic enzymes in tumorigen-
esis. Oncogene. 2017;36(19):2629–36.
 66. Tas SW, Maracle CX, Balogh E, Szekanecz Z. Targeting of proangiogenic 
signalling pathways in chronic inflammation. Nat Rev Rheumatol. 
2016;12(2):111–22.
 67. Del Rey MJ, Izquierdo E, Usategui A, Gonzalo E, Blanco FJ, Acquadro F, 
et al. The transcriptional response of normal and rheumatoid arthritis 
synovial fibroblasts to hypoxia. Arthritis Rheum. 2010;62(12):3584–94.
 68. Biniecka M, Fox E, Gao W, Ng CT, Veale DJ, Fearon U, et al. Hypoxia 
induces mitochondrial mutagenesis dysfunction in inflammatory 
arthritis. 2011;63(8):2172–82.
 69. Veale DJ, Fearon U. Inhibition of angiogenic pathways in rheumatoid 
arthritis: potential for therapeutic targeting. Best Pract Res Clin Rheu-
matol. 2006;20(5):941–7.
 70. Lu Y, Yu SS, Zong M, Fan SS, Lu TB, Gong RH, et al. Glucose-6-Phosphate 
Isomerase (G6PI) Mediates Hypoxia-Induced Angiogenesis in Rheuma-
toid Arthritis. Sci Rep. 2017;7:40274.
 71. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH, et al. The 
succinate receptor GPR91 in neurons has a major role in retinal angio-
genesis. Nat Med. 2008;14(10):1067–76.
 72. MacDonald IJ, Liu SC, Su CM, Wang YH, Tsai CH, Tang CH. Implications of 
angiogenesis involvement in arthritis. Int J Mol Sci. 2018;19:7.
 73. Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S. 
The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogen-
esis. 2015;18(4):433–48.
 74. Scott BB, Weisbrot LM, Greenwood JD, Bogoch ER, Paige CJ, Keystone 
EC. Rheumatoid arthritis synovial fibroblast and U937 macrophage/
monocyte cell line interaction in cartilage degradation. Arthritis Rheum. 
1997;40(3):490–8.
 75. Peters MA, Wendholt D, Strietholt S, Frank S, Pundt N, Korb-Pap A, et al. 
The loss of alpha2beta1 integrin suppresses joint inflammation and 
cartilage destruction in mouse models of rheumatoid arthritis. Arthritis 
Rheum. 2012;64(5):1359–68.
 76. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, 
Firestein GS. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular 
cell adhesion molecule-1 expression in synovium and on fibroblast-like 
synoviocytes. J Immunol. 1992;149(4):1424–31.
 77. McInnes IB, Leung BP, Liew FY. Cell-cell interactions in synovitis. 
Interactions between T lymphocytes and synovial cells. Arthritis Res. 
2000;2(5):374–8.
 78. Ata R, Antonescu CN. Integrins and cell metabolism: an intimate rela-
tionship impacting cancer. Int J Mol Sci. 2017;18:1.
 79. Suto T, Karonitsch T. The immunobiology of mTOR in autoimmunity. J 
Autoimmun. 2020;110:102373.
 80. Cantor JM, Ginsberg MH. CD98 at the crossroads of adaptive immunity 
and cancer. J Cell Sci. 2012;125(Pt 6):1373–82.
 81. Tang MW, Malvar Fernandez B, Newsom SP, van Buul JD, Radstake T, 
Baeten DL, et al. Class 3 semaphorins modulate the invasive capacity 
of rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology. 
2018;57(5):909–20.
 82. Remmers EF, Sano H, Wilder RL. Platelet-derived growth factors 
and heparin-binding (fibroblast) growth factors in the synovial 
tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum. 
1991;21(3):191–9.
 83. Shibuya H, Yoshitomi H, Murata K, Kobayashi S, Furu M, Ishikawa M, 
et al. TNFalpha, PDGF, and TGFbeta synergistically induce synovial lining 
hyperplasia via inducible PI3Kdelta. Mod Rheumatol. 2015;25(1):72–8.
 84. Thornton SC, Por SB, Penny R, Richter M, Shelley L, Breit SN. Identifica-
tion of the major fibroblast growth factors released spontaneously in 
inflammatory arthritis as platelet derived growth factor and tumour 
necrosis factor-alpha. Clin Exp Immunol. 1991;86(1):79–86.
 85. Rosengren S, Corr M, Boyle DL. Platelet-derived growth factor and 
transforming growth factor beta synergistically potentiate inflamma-
tory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res 
Ther. 2010;12(2):R65.
 86. Lauzier A, Lavoie RR, Charbonneau M, Gouin-Boisvert B, Harper K, 
Dubois CM. Snail Is a Critical Mediator of Invadosome Formation and 
Joint Degradation in Arthritis. Am J Pathol. 2016;186(2):359–74.
Page 12 of 13Mousavi et al. Autoimmun Highlights            (2021) 12:3 
 87. Laragione T, Brenner M, Li W, Gulko PS. Cia5d regulates a new fibroblast-
like synoviocyte invasion-associated gene expression signature. 
Arthritis Res Ther. 2008;10(4):R92.
 88. Xue SN, Lei J, Lin DZ, Yang C, Yan L. Changes in biological behaviors of 
rat dermal fibroblasts induced by high expression of MMP9. World J 
Emerg Med. 2014;5(2):139–43.
 89. Ai R, Laragione T, Hammaker D, Boyle DL, Wildberg A, Maeshima K, 
et al. Comprehensive epigenetic landscape of rheumatoid arthritis 
fibroblast-like synoviocytes. Nat Commun. 2018;9(1):1921.
 90. Li D, Chen F, Ding J, Lin N, Li Z, Wang X. Knockdown of HIP1 expression 
promotes ligand–induced endocytosis of EGFR in HeLa cells. Oncol 
Rep. 2017;38(6):3387–91.
 91. Wang J, Yu M, Guo Q, Ma Q, Hu C, Ma Z, et al. Prognostic significance 
of huntingtin interacting protein 1 expression on patients with acute 
myeloid leukemia. Sci Rep. 2017;7:45960.
 92. Wang J, Yu M, Guo Q, Ma Q, Hu C, Ma Z, et al. Prognostic significance 
of huntingtin interacting protein 1 expression on patients with acute 
myeloid leukemia. Sci Rep. 2017;7:45960.
 93. Igarashi H, Hirano H, Yahagi A, Saika T, Ishihara KJCI. Anti-apoptotic 
roles for the mutant p53R248Q through suppression of p53-regulated 
apoptosis-inducing protein 1 in the RA-derived fibroblast-like synovio-
cyte cell line MH7A. Resist. 2014;150(1):12–21.
 94. Yamanishi Y, Boyle DL, Green DR, Keystone EC, Connor A, Zollman S, 
et al. p53 tumor suppressor gene mutations in fibroblast-like synovio-
cytes from erosion synovium and non-erosion synovium in rheumatoid 
arthritis. Gene. 2004;7(1):R12.
 95. Lee YH, Ji JD, Kim A, Kim CH, Song GGJTKjoim. Expression of p53 protein 
in rheumatoid arthritis synovium. An immunohistochemical analysis. 
1999;14(1):59.
 96. Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apop-
tosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis 
synovium. Am J Pathol. 1996;149(6):2143.
 97. Xiao P, Hao Y, Zhu X, Wu X. p53 contributes to quercetin-induced 
apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. 
Inflammation. 2013;36(2):272–8.
 98. Zhang T, Li H, Shi J, Li S, Li M, Zhang L, et al. p53 predominantly 
regulates IL-6 production and suppresses synovial inflammation in 
fibroblast-like synoviocytes and adjuvant-induced arthritis. Arthritis 
research therapy. 2016;18(1):271.
 99. Rème T, Travaglio A, Gueydon E, Adla L, Jorgensen C, Sany JJC, et al. 
Mutations of the p53 tumour suppressor gene in erosive rheumatoid 
synovial tissue.  Gene 1998;111(2):353.
 100. Guo X, Zhang D, Zhang X, Jiang J, Xue P, Wu C, et al. Dyrk1A promotes 
the proliferation, migration and invasion of fibroblast-like synoviocytes 
in rheumatoid arthritis via down-regulating Spry2 and activating the 
ERK MAPK pathway. 2018;55:63–70.
 101. Weisbart RH, Chan G, Heinze E, Mory R, Nishimura RN, Colburn KJJoBC. 
BRAF drives synovial fibroblast transformation in rheumatoid arthritis. 
2010;285(45):34299–303.
 102. Liu F, Feng XX, Zhu SL, Huang HY, Chen YD, Pan YF, et al. Sonic 
Hedgehog Signaling Pathway Mediates Proliferation and Migration 
of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via MAPK/ERK 
Signaling Pathway. Front Immunol. 2018;9:2847.
 103. Lard L, Van Gaalen F, Schonkeren J, Pieterman E, Stoeken G, Vos K, et al. 
Association of the–2849 interleukin-10 promoter polymorphism with 
autoantibody production and joint destruction in rheumatoid arthritis. 
2003;48(7):1841–8.
 104. Aslani S, Mahmoudi M, Karami J, Jamshidi AR, Malekshahi Z, Nicknam 
MH. Epigenetic alterations underlying autoimmune diseases. Autoim-
munity. 2016;49(2):69–83.
 105. Karami J, Aslani S, Tahmasebi MN, Mousavi MJ, Sherafat Vaziri A, 
Jamshidi A, et al. Epigenetics in rheumatoid arthritis; fibroblast-like 
synoviocytes as an emerging paradigm in the disease pathogenesis. 
Immunology and Cell Biology. 2019.
 106. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA 
methylome signature in rheumatoid arthritis. Ann Rheum Dis. 
2013;72(1):110–7.
 107. Frank-Bertoncelj M, Trenkmann M, Klein K, Karouzakis E, Rehrauer H, 
Bratus A, et al. Epigenetically-driven anatomical diversity of synovial 
fibroblasts guides joint-specific fibroblast functions. Nat Commun. 
2017;8:14852.
 108. Rhead B, Holingue C, Cole M, Shao X, Quach HL, Quach D, et al. 
Rheumatoid Arthritis Naive T Cells Share Hypermethylation Sites With 
Synoviocytes. Arthritis Rheumatol. 2017;69(3):550–9.
 109. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: 
passive responders and imprinted aggressors. Nat Rev Rheumatol. 
2013;9(1):24.
 110. Ai R, Whitaker JW, Boyle DL, Tak PP, Gerlag DM, Wang W, et al. DNA 
methylome signature in synoviocytes from patients with early rheuma-
toid arthritis compared to synoviocytes from patients with longstand-
ing rheumatoid arthritis. Arthritis rheumatology. 2015;67(7):1978–80.
 111. Matsuda S, Hammaker D, Topolewski K, Briegel KJ, Boyle DL, Dowdy 
S, et al. Regulation of the cell cycle and inflammatory arthritis by 
the transcription cofactor LBH gene. The Journal of Immunology. 
2017:ji1700719.
 112. Hammaker D, Whitaker JW, Maeshima K, Boyle DL, Ekwall AKH, Wang W, 
et al. LBH gene transcription regulation by the interplay of an enhancer 
risk allele and DNA methylation in rheumatoid arthritis. Arthritis Rheu-
matology. 2016;68(11):2637–45.
 113. Maeshima K, Stanford SM, Hammaker D, Sacchetti C, Zeng L-F, Ai R, 
et al. Abnormal PTPN11 enhancer methylation promotes rheumatoid 
arthritis fibroblast-like synoviocyte aggressiveness and joint inflamma-
tion. JCI Insight. 2016;1:7.
 114. Neidhart M, Rethage J, Kuchen S, Künzler P, Crowl RM, Billingham ME, 
et al. Retrotransposable L1 elements expressed in rheumatoid arthritis 
synovial tissue: association with genomic DNA hypomethylation and 
influence on gene expression. Arthr Rhuem. 2000;43(12):2634–47.
 115. Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, 
et al. The role of p38 mitogen-activated protein kinase in IL‐6 and IL‐8 
production from the TNF‐α‐or IL‐1β‐stimulated rheumatoid synovial 
fibroblasts. FEBS Lett. 2000;465(1):23–7.
 116. Ravanti L, Heino J, López-Otín C, Kähäri V-M. Induction of collagenase-3 
(MMP-13) expression in human skin fibroblasts by three-dimensional 
collagen is mediated by p38 mitogen-activated protein kinase. J Biol 
Chem. 1999;274(4):2446–55.
 117. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. 
Expression and function of histone deacetylases in rheumatoid arthritis 
synovial fibroblasts. J Rhuematol. 2009;36(8):1580–9.
 118. Glozak M, Seto E. Histone deacetylases and cancer. Oncogene. 
2007;26(37):5420.
 119. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase 
inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and 
macrophage IL-6 production by accelerating mRNA decay. Ann Rheum 
Dis. 2012;71(3):424–31.
 120. Jüngel A, Baresova V, Ospelt C, Simmen BR, Michel BA, Gay RE, et al. 
Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for 
TRAIL-induced apoptosis. Ann Rheum Dis. 2006;65(7):910–2.
 121. Morinobu A, Wang B, Liu J, Yoshiya S, Kurosaka M, Kumagai S. Trichosta-
tin A cooperates with Fas-mediated signal to induce apoptosis in rheu-
matoid arthritis synovial fibroblasts. J Rhuematol. 2006;33(6):1052–60.
 122. Nakamura C, Matsushita I, Kosaka E, Kondo T, Kimura T. Anti-arthritic 
effects of combined treatment with histone deacetylase inhibitor and 
low-intensity ultrasound in the presence of microbubbles in human 
rheumatoid synovial cells. Rheumatology. 2008;47(4):418–24.
 123. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone 
deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769.
 124. Joosten LA, Leoni F, Meghji S, Mascagni P. Inhibition of HDAC activity 
by ITF2357 ameliorates joint inflammation and prevents cartilage 
and bone destruction in experimental arthritis. Molecular medicine. 
2011;17(5–6):391–6.
 125. Juan L-J, Shia W-J, Chen M-H, Yang W-M, Seto E, Lin Y-S, et al. Histone 
deacetylases specifically down-regulate p53-dependent gene activa-
tion. J Biol Chem. 2000;275(27):20436–43.
 126. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N, et al. 
Trichostatin A, a histone deacetylase inhibitor, suppresses synovial 
inflammation and subsequent cartilage destruction in a collagen 
antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 
2008;16(6):723–32.
 127. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, et al. 
Anti-rheumatic activities of histone deacetylase (HDAC) inhibi-
tors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 
2007;150(7):862–72.
Page 13 of 13Mousavi et al. Autoimmun Highlights            (2021) 12:3  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 128. Mu N, Gu J, Huang T, Zhang C, Shu Z, Li M, et al. A novel NF-κB/
YY1/microRNA-10a regulatory circuit in fibroblast-like synoviocytes 
regulates inflammation in rheumatoid arthritis. Scientific reports. 
2016;6:20059.
 129. Hussain N, Zhu W, Jiang C, Xu J, Wu X, Geng M, et al. Down-regulation 
of miR‐10a‐5p in synoviocytes contributes to TBX5‐controlled joint 
inflammation. J Cell Mol Med. 2018;22(1):241–50.
 130. Li D, Wang Y, Xu N, Wei Q, Wu M, Li X, et al. Follistatin-like protein 1 is 
elevated in systemic autoimmune diseases and correlated with disease 
activity in patients with rheumatoid arthritis. Arthritis research therapy. 
2011;13(1):R17.
 131. Hong W, Zhang P, Wang X, Tu J, Wei W. The Effects of MicroRNAs on 
Key Signalling Pathways and Epigenetic Modification in Fibroblast-
Like Synoviocytes of Rheumatoid Arthritis. Mediators of inflammation. 
2018;2018.
 132. Salehi E, Eftekhari R, Oraei M, Gharib A, Bidad K. MicroRNAs in rheuma-
toid arthritis. Clin Rheumatol. 2015;34(4):615–28.
 133. Niederer F, Trenkmann M, Ospelt C, Karouzakis E, Neidhart M, Stanczyk 
J, et al. Down-regulation of microRNA‐34a* in rheumatoid arthritis 
synovial fibroblasts promotes apoptosis resistance. Arthr Rhuem. 
2012;64(6):1771–9.
 134. Vicente R, Noël D, Pers Y-M, Apparailly F, Jorgensen C. Deregulation 
and therapeutic potential of microRNAs in arthritic diseases. Nat Rev 
Rheumatol. 2016;12(4):211.
 135. Gao J, Zhou X-L, Kong R-N, Ji L-M, He L-L, Zhao D-B. microRNA-126 
targeting PIK3R2 promotes rheumatoid arthritis synovial fibro-blasts 
proliferation and resistance to apoptosis by regulating PI3K/AKT path-
way. Exp Mol Pathol. 2016;100(1):192–8.
 136. Zhou Q, Long L, Shi G, Zhang J, Wu T, Zhou B. Research of the methyla-
tion status of miR-124a gene promoter among rheumatoid arthritis 
patients. Clinical and Developmental Immunology. 2013;2013.
 137. Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, et al. The 
role of miRNA in inflammation and autoimmunity. Autoimmun rev. 
2013;12(12):1160–5.
 138. Saferding V, Puchner A, Goncalves-Alves E, Hofmann M, Bonelli M, 
Brunner JS, et al. MicroRNA-146a governs fibroblast activation and joint 
pathology in arthritis. J Autoimmun. 2017;82:74–84.
 139. Chen X-M, Huang Q-C, Yang S-L, Chu Y-L, Yan Y-H, Han L, et al. Role of 
micro RNAs in the pathogenesis of rheumatoid arthritis: novel perspec-
tives based on review of the literature. Medicine. 2015;94(31).
 140. Yang S, Yang Y. Downregulation of microRNA–221 decreases migration 
and invasion in fibroblast–like synoviocytes in rheumatoid arthritis. Mol 
Med Rep. 2015;12(2):2395–401.
 141. Miao C-g, Shi W-j, Xiong Y-y, Yu H, Zhang X-l, Qin M-s, et al. Micro-
RNA-663 activates the canonical Wnt signaling through the adenoma-
tous polyposis coli suppression. Immunology letters. 2015;166(1):45–54.
 142. Chen Y, Xian P-F, Yang L, Wang S-X. MicroRNA-21 promotes prolifera-
tion of fibroblast-like synoviocytes through mediation of NF-κB nuclear 
translocation in a rat model of collagen-induced rheumatoid arthritis. 
BioMed research international. 2016;2016.
 143. Shi X, Sun M, Liu H, Yao Y, Song YJCl. Long non-coding RNAs: a new 
frontier in the study of human diseases. 2013;339(2):159–66.
 144. Mercer TR, Dinger ME, Mattick JSJNrg. Long non-coding RNAs: insights 
into functions. 2009;10(3):155.
 145. Ye Y, Gao X, Yang N. LncRNA ZFAS1 promotes cell migration and 
invasion of fibroblast-like synoviocytes by suppression of miR-27a in 
rheumatoid arthritis. Hum Cell. 2018;31(1):14–21.
 146. Pan F, Zhu L, Lv H, Pei C. Quercetin promotes the apoptosis of fibro-
blast-like synoviocytes in rheumatoid arthritis by upregulating lncRNA 
MALAT1. Int J Mol Med. 2016;38(5):1507–14.
 147. Miao C-g, Yang Y-y, He X, Xu T, Huang C, Huang Y, et al. New advances of 
microRNAs in the pathogenesis of rheumatoid arthritis, with a focus on 
the crosstalk between DNA methylation and the microRNA machinery. 
Cellular signalling. 2013;25(5):1118–25.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
